Latest & greatest articles for migraine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on migraine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on migraine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for migraine

3. Acupuncture shows promise for preventing episodic migraines

Acupuncture shows promise for preventing episodic migraines Signal - Acupuncture shows promise for preventing episodic migraines Dissemination Centre Discover Portal NIHR DC Discover Acupuncture shows promise for preventing episodic migraines Published on 18 October 2016 Acupuncture was about as effective as long term medication in reducing the number of migraines. There were fewer adverse events amongst people receiving acupuncture (16-17%) compared to drug treatment (34%). Migraines affect (...) , in reality, only be available to people living in certain areas or who can afford to pay for treatment themselves. Share your views on the research. Why was this study needed? Migraines are common, affecting around one in five women and one in 15 men. Symptoms include headache, visual disturbances and nausea, which can be severe enough to stop people living their normal daily life. Migraine attacks last anywhere between four and 72 hours and are estimated to cost the UK economy as much as £2 billion

NIHR Dissemination Centre2018

4. “Triptans” can relieve migraines in children and adolescents

“Triptans” can relieve migraines in children and adolescents Signal - “Triptans” can relieve migraines in children and adolescents Dissemination Centre Discover Portal NIHR DC Discover “Triptans” can relieve migraines in children and adolescents Published on 13 September 2016 Triptans, a migraine medication, relieve migraine headache completely within two hours compared to placebo. Ibuprofen was also effective but less well studied. This review was also reassuring in that any side effects (...) of treatment were mild. Most evidence identified in this Cochrane review was for sumatriptan, a commonly prescribed treatment for adults, compared to placebo or dummy pills. A few studies examined other triptans or other painkillers, such as ibuprofen or paracetamol against placebo in children and adults. The findings support current guideline recommendations to prescribe nasal triptans for migraine in adolescents. Only nasal preparations are currently licensed for adolescents, whereas oral administration

NIHR Dissemination Centre2018

5. Acupuncture for migraine headaches

Acupuncture for migraine headaches Acupuncture for migraine headaches Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics Acupuncture for migraine headaches View/ Open Date 2010-04 Format Metadata Abstract Acupuncture reduces the frequency of migraine headaches when used as an adjunct to, or in place of, medical management

Clinical Inquiries2018

6. The combination of magnesium, riboflavin, and coenzyme Q10 for migraine prophylaxis

The combination of magnesium, riboflavin, and coenzyme Q10 for migraine prophylaxis The combination of magnesium, riboflavin, and coenzyme Q10 for migraine prophylaxis – Morsels of Evidence \t\t\t\r\n\t\t\t \t\t\t\r\n\t\t\t Like this: Like Loading... ","author":{"@type":"Person","name":"Michael Tam"},"image":["https:\/\/evidencebasedmedicine.com.au\/wp-content\/uploads\/2018\/10\/cover.png"]} Toggle search form Toggle navigation Evidence-based medicine for general practitioners Oct 19 2018 (...) The combination of magnesium, riboflavin, and coenzyme Q10 for migraine prophylaxis By in , , Journal reference: Gaul C, Diener HC, Danesch U, Migravent Study G. Improvement of migraine symptoms with a proprietary supplement containing riboflavin, magnesium and Q10: a randomized, placebo-controlled, double-blind, multicenter trial. J Headache Pain 2015;16:516. Link: Published: April 2015 Evidence cookie says… The evidence for combination magnesium, riboflavin, and CoQ10 is at best equivocal for migraine

Morsels of Evidence2018

7. Migraine headache in adults

Migraine headache in adults Migraine headache in adults - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Migraine headache in adults Last reviewed: September 2018 Last updated: August 2018 Important updates Erenumab approved in the EU for the prevention of migraine Erenumab, a novel treatment for migraine prevention, has been approved by the European Medicines Agency (EMA) for the prophylaxis of migraine in adults who (...) have at least 4 migraine days per month. Erenumab is a first-in-class fully human monoclonal antibody that works by inhibiting the calcitonin gene‑related peptide (CGRP) receptors. The CGRP is believed to play a causal role in the pathophysiology of migraine. Erenumab is administered as a once-monthly subcutaneous injection. According to the EMA, the benefit of erenumab treatment is its ability to reduce the number of monthly migraine days. In two trials involving 667 patients with chronic migraine

BMJ Best Practice2018

8. Fremanezumab for preventive treatment of migraine: Functional status on headache-free days

Fremanezumab for preventive treatment of migraine: Functional status on headache-free days 30120138 2018 08 18 1526-632X 2018 Aug 17 Neurology Neurology Fremanezumab for preventive treatment of migraine: Functional status on headache-free days. 10.1212/01.wnl.0000544321.19316.40 10.1212/01.wnl.0000544321.19316.40 To evaluate the effect of fremanezumab on the functional status on headache-free days in phase 2 episodic migraine (EM) and chronic migraine (CM) studies. Functional status data were (...) with fremanezumab. There was an increased number of headache-free days with normal functional performance on all measures for the patients with EM and some measures for patients with CM in the fremanezumab-treated groups. Further research is required to confirm these findings in a prospective study and to clarify the underlying mechanism(s). NCT02025556 and NCT02021773. This study provides Class II evidence that for patients with migraine, fremanezumab increases normal functional performance on headache-free

EvidenceUpdates2018

9. Common migraine prevention treatments found to be equally effective

Common migraine prevention treatments found to be equally effective Signal - Common migraine prevention treatments found to be equally effective Dissemination Centre Discover Portal NIHR DC Discover Common migraine prevention treatments found to be equally effective Published on 24 September 2015 This review found that the main drugs used for preventing migraine were all effective compared with placebo or dummy treatment. The results were less clear cut when comparing drugs directly against (...) each other as there were fewer trials. This review highlights the range of drugs used to prevent migraines, reflecting the number of possible treatments available. The review’s conclusions suggest that the prescriber could be guided by individual patient characteristics, including preferences, pre-existing conditions and potential side effects. This review confirms and strengthens NICE guidance in this area. Share your views on the research. Why was this study needed? Migraines affect around 15

NIHR Dissemination Centre2018

12. Migraine

Migraine Top results for migraine - Trip Database or use your Google+ account Turning Research Into Practice My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing (...) the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for migraine The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines

Trip Latest and Greatest2018

14. Noninvasive vagus nerve stimulation as acute therapy for migraine: The randomized PRESTO study

Noninvasive vagus nerve stimulation as acute therapy for migraine: The randomized PRESTO study 29907608 2018 06 16 1526-632X 2018 Jun 15 Neurology Neurology Noninvasive vagus nerve stimulation as acute therapy for migraine: The randomized PRESTO study. 10.1212/WNL.0000000000005857 10.1212/WNL.0000000000005857 To evaluate the efficacy, safety, and tolerability of noninvasive vagus nerve stimulation (nVNS; gammaCore; electroCore, LLC, Basking Ridge, NJ) for the acute treatment of migraine (...) in a multicenter, double-blind, randomized, sham-controlled trial. A total of 248 participants with episodic migraine with/without aura were randomized to receive nVNS or sham within 20 minutes from pain onset. Participants were to repeat treatment if pain had not improved in 15 minutes. nVNS (n = 120) was superior to sham (n = 123) for pain freedom at 30 minutes (12.7% vs 4.2%; p = 0.012) and 60 minutes (21.0% vs 10.0%; p = 0.023) but not at 120 minutes (30.4% vs 19.7%; p = 0.067; primary endpoint; logistic

EvidenceUpdates2018

15. Migraine

Migraine Autosynthesis - Trip Database or use your Google+ account Turning Research Into Practice My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search

Trip Evidence Maps2018

16. Botulinum toxins for the prevention of migraine in adults.

Botulinum toxins for the prevention of migraine in adults. BACKGROUND: Migraine occurs in around 15% of adults and is ranked as the seventh most disabling disease amongst all diseases globally. Despite the available treatments many people suffer prolonged and frequent attacks which have a major impact on their quality of life. Chronic migraine is defined as 15 or more days of headache per month, at least eight of those days being migraine. People with episodic migraine have fewer than 15 (...) headache days per month. Botulinum toxin type A has been licensed in some countries for chronic migraine treatment, due to the results of just two trials. OBJECTIVES: To assess the effects of botulinum toxins versus placebo or active treatment for the prevention or reduction in frequency of chronic or episodic migraine in adults. SEARCH METHODS: We searched CENTRAL, MEDLINE & MEDLINE in Process, Embase, ClinicalTrials.gov and World Health Organization International Clinical Trials Registry

Cochrane2018

18. Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial.

Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial. Importance: Fremanezumab, a fully humanized monoclonal antibody that targets calcitonin gene-related peptide, may be effective for treating episodic migraine. Objective: To assess the efficacy of fremanezumab compared with placebo for prevention of episodic migraine with a monthly dosing regimen or a single higher dose. Design and Setting: Randomized, double-blind, placebo-controlled (...) , parallel-group trial conducted at 123 sites in 9 countries from March 23, 2016 (first patient randomized), to April 10, 2017, consisting of a screening visit, 28-day pretreatment period, 12-week treatment period, and final evaluation at week 12. Participants: Study participants were aged 18 to 70 years with episodic migraine (6-14 headache days, with at least 4 migraine days, during 28-day pretreatment period). Patients who had previous treatment failure with 2 classes of migraine-preventive medication

JAMA2018

19. Acupuncture shows promise for preventing episodic migraines

Acupuncture shows promise for preventing episodic migraines NIHR DC | Signal - Acupuncture shows promise for preventing episodic migraines Dissemination Centre Discover Portal NIHR DC Discover NIHR Signal Acupuncture shows promise for preventing episodic migraines Published on 18 October 2016 Acupuncture was about as effective as long term medication in reducing the number of migraines. There were fewer adverse events amongst people receiving acupuncture (16-17%) compared to drug treatment (34 (...) %). Migraines affect around one in seven people in the UK. Their unpleasant symptoms last between four and 72 hours and can impact on people’s ability to do everyday tasks, such as going to work. This systematic review looked at acupuncture delivered at least once a week for up to six sessions, similar to the NICE recommendation of up to ten sessions over five to eight - weeks. Acupuncture may be a preventative treatment option for those willing to have it but NHS provision of acupuncture is variable

NIHR Dissemination Centre2018

20. “Triptans” can relieve migraines in children and adolescents

“Triptans” can relieve migraines in children and adolescents NIHR DC | Signal - “Triptans” can relieve migraines in children and adolescents Dissemination Centre Discover Portal NIHR DC Discover NIHR Signal “Triptans” can relieve migraines in children and adolescents Published on 13 September 2016 Triptans, a migraine medication, relieve migraine headache completely within two hours compared to placebo. Ibuprofen was also effective but less well studied. This review was also reassuring (...) in that any side effects of treatment were mild. Most evidence identified in this Cochrane review was for sumatriptan, a commonly prescribed treatment for adults, compared to placebo or dummy pills. A few studies examined other triptans or other painkillers, such as ibuprofen or paracetamol against placebo in children and adults. The findings support current guideline recommendations to prescribe nasal triptans for migraine in adolescents. Only nasal preparations are currently licensed for adolescents

NIHR Dissemination Centre2018